Critics slam FDA bonus program

In 2004, Congress expanded an FDA bonus program designed to attract and retain highly skilled regulators. The measure was enacted to prevent a mass exodus of FDA workers to more highly-paid jobs in the private sector. But now critics say the bonus program has gotten out of hand. Many of the largest bonuses go to already well-compensated officials rather than the FDA scientists, inspectors and doctors most likely to defect. Additionally, the average FDA worker makes double the average federal government employee, and many think it's money not well spent. Critics point to the recent rash of food-borne diseases as a sign that the effort to keep FDA employees isn't translating into better regulation and oversight. FDA officials, on the other hand, says that a lower turn-over rate is a sign that the bonuses are doing what they should.

- see this Washington Post article for more

Related Articles:
FDA bonuses used to keep regulators in-house. Report
IOM slams FDA, calls for major reforms. Report
Experts question use of approvable letters. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.